2025 NOSCM | Waldenstrom’s Macroglobulinemia

2025 NOSCM | Waldenstrom’s Macroglobulinemia

0% Complete

Course Overview

Dr. Morie Gertz reviewed Waldenstrom's macroglobulinemia, noting M spike, hyperviscosity, and lymphoplasmacytic cells. Treatments include rituximab-bendamustine and BTK inhibitors, with Zanubrutinib favored for lower toxicity. Patient input and individual factors guide therapy choices.

Course Content

Credits

  • AMA PRA Category 1 Credit™Non-CME

Course Details

Duration
0.00 hour
Released
Jul 31, 2025
Last Review
Jul 31, 2025
Expires
Jul 31, 2026

Target Audience

Physicians
Nurses
Pharmacists
Physician Associates

Faculty & Disclosure

Faculty

Morie A. Gertz, MD, MACP

Accreditation

NA